FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH,

BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ( “BioVaxys”), is pleased to announce today that the US Food and Drug Administration (“FDA”) has provided its official Written Response …, BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ( “BioVaxys”), is pleased to announce today that the US Food and Drug Administration (“FDA”) has provided its official Written Response …, Read More

Scroll to Top